WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Central Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
cnbc | April 17, 2020
Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir...
Industrial Impact, Medical
Prnewswire | March 30, 2023
Elemental Machines, developer of the Intelligent Operations Platform, has entered into a partnership with System-c bioprocess as an authorized reseller of Elemental Machines' hardware solutions, servicing the biopharmaceutical industry in France. The partnership will allow Elemental Machines to expand its footprint further in European markets. System-c serves as a partner and distributor for benchmark brands that cover a range of bioprocessing products from screening to filt...
Industrial Impact
Merakris Therapeutics | February 09, 2022
Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...
Cell and Gene Therapy
iXCells Biotechnologies | September 30, 2022
iXCells Biotechnologies a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners a private investment firm focusing on the healthcare industry. “iXCells is delighted to join GPP’s portfolio of ...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE